These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36155307)

  • 21. Neurocognitive correlates of the varied domains of outcomes at 20 year follow-up of first-episode psychosis.
    Cuesta MJ; Sánchez-Torres AM; Moreno-Izco L; García de Jalón E; Gil-Berrozpe GJ; Zarzuela A; Peralta V; Ballesteros A; Fañanás L; Hernández R; Janda L; Lorente R; Papiol S; Peralta D; Ribeiro M; Rosero A; Zandio M
    Psychiatry Res; 2022 Dec; 318():114933. PubMed ID: 36334328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of anticholinergic burden on brain activity during Working Memory and real-world functioning in patients with schizophrenia.
    Selvaggi P; Fazio L; Toro VD; Mucci A; Rocca P; Martinotti G; Cascino G; Siracusano A; Zeppegno P; Pergola G; Bertolino A; Blasi G; Galderisi S;
    Schizophr Res; 2023 Oct; 260():76-84. PubMed ID: 37633126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of time and duration of untreated psychosis on cognitive and social functioning in Chinese patients with first-episode schizophrenia: A 1-year study.
    Heeramun-Aubeeluck A; Liu N; Fischer F; Huang N; Chen F; He L; Yang C; Luo Y; Lu Z
    Nord J Psychiatry; 2015 May; 69(4):254-61. PubMed ID: 25731069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders.
    Dauphinot V; Mouchoux C; Veillard S; Delphin-Combe F; Krolak-Salmon P
    Alzheimers Res Ther; 2017 Aug; 9(1):58. PubMed ID: 28764796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients.
    Chen EY; Hui CL; Dunn EL; Miao MY; Yeung WS; Wong CK; Chan WF; Tang WN
    Schizophr Res; 2005 Sep; 77(1):99-104. PubMed ID: 16005389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study.
    O'Reilly K; O'Connell P; Donohoe G; Coyle C; O'Sullivan D; Azvee Z; Maddock C; Sharma K; Sadi H; McMahon M; Kennedy HG
    Psychol Med; 2016 Nov; 46(15):3199-3211. PubMed ID: 27576609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticholinergic medication burden and cognitive function in participants of the ASPREE study.
    Broder JC; Ryan J; Shah RC; Lockery JE; Orchard SG; Gilmartin-Thomas JF; Fravel MA; Owen AJ; Woods RL; Wolfe R; Storey E; Murray AM; Ernst ME
    Pharmacotherapy; 2022 Feb; 42(2):134-144. PubMed ID: 34866212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment.
    McCleery A; Ventura J; Kern RS; Subotnik KL; Gretchen-Doorly D; Green MF; Hellemann GS; Nuechterlein KH
    Schizophr Res; 2014 Aug; 157(1-3):33-9. PubMed ID: 24888526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration?
    Becker HE; Nieman DH; Wiltink S; Dingemans PM; van de Fliert JR; Velthorst E; de Haan L; van Amelsvoort TA; Linszen DH
    Psychol Med; 2010 Oct; 40(10):1599-606. PubMed ID: 20132582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.
    Eum S; Hill SK; Alliey-Rodriguez N; Stevenson JM; Rubin LH; Lee AM; Mills LJ; Reilly JL; Lencer R; Keedy SK; Ivleva E; Keefe RSE; Pearlson GD; Clementz BA; Tamminga CA; Keshavan MS; Gershon ES; Sweeney JA; Bishop JR
    Neuropsychopharmacology; 2021 Sep; 46(10):1802-1810. PubMed ID: 34145405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association of cognitive impairment with quality of life and functional impairment in Ugandan first-episode psychosis patients: a cross sectional study.
    Mwesiga EK; Ssemata AS; Gumikiriza J; Nanteza A; Nakitende AJ; Nakku J; Akena D; Nakasujja N
    Health Qual Life Outcomes; 2022 Jul; 20(1):113. PubMed ID: 35870969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying neurocognitive markers for outcome prediction of global functioning in individuals with first-episode and ultra-high-risk for psychosis.
    Sawada K; Kanehara A; Sakakibara E; Eguchi S; Tada M; Satomura Y; Suga M; Koike S; Kasai K
    Psychiatry Clin Neurosci; 2017 May; 71(5):318-327. PubMed ID: 28294477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia.
    Hou CL; Xiang YT; Wang ZL; Everall I; Tang Y; Yang C; Xu MZ; Correll CU; Jia FJ
    Schizophr Res; 2016 Jul; 174(1-3):71-76. PubMed ID: 27197904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?
    Bang M; Kim KR; Song YY; Baek S; Lee E; An SK
    Aust N Z J Psychiatry; 2015 May; 49(5):462-70. PubMed ID: 25425742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients.
    Joshi YB; Thomas ML; Hochberger WC; Bismark AW; Treichler EBH; Molina J; Nungaray J; Cardoso L; Sprock J; Swerdlow NR; Light GA
    Schizophr Res; 2019 Jun; 208():384-389. PubMed ID: 30738698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis.
    Mata I; Rodríguez-Sánchez JM; Pelayo-Terán JM; Pérez-Iglesias R; González-Blanch C; Ramírez-Bonilla M; Martínez-García O; Vázquez-Barquero JL; Crespo-Facorro B
    Psychol Med; 2008 Sep; 38(9):1257-66. PubMed ID: 18005495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment and self-reported side effects in the euthymic phase of bipolar disorders: Results from the FACE-BD cohort.
    Vidal N; Brunet-Gouet E; Frileux S; Aouizerate B; Aubin V; Belzeaux R; Courtet P; D'Amato T; Dubertret C; Etain B; Haffen E; Januel D; Leboyer M; Lefrere A; Llorca PM; Marlinge E; Olié E; Polosan M; Schwan R; Walter M; ; Passerieux C; Roux P
    Eur Neuropsychopharmacol; 2023 Dec; 77():67-79. PubMed ID: 37741163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of anticholinergic burden of psychiatric medications on major outcome domains of psychotic disorders: A 21-year prospective cohort study.
    Peralta V; de Jalón EG; Moreno-Izco L; Peralta D; Janda L; Sánchez-Torres AM; Cuesta MJ;
    Schizophr Res; 2024 Feb; 264():386-393. PubMed ID: 38237360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between diminished expression and cognitive impairment in first-episode schizophrenia: a prospective three-year follow-up study.
    Chang WC; Hui CL; Chan SK; Lee EH; Wong GH; Chen EY
    Schizophr Res; 2014 Jan; 152(1):146-51. PubMed ID: 24333004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.